Refereed journal article or data article (A1)

Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients




List of Authors: Katariina Hänninen, Olli Jääskeläinen, Sanna‐Kaisa Herukka, Merja Soilu‐Hänninen

Publisher: WILEY

Publication year: 2020

Journal: Brain and Behavior

Journal name in source: BRAIN AND BEHAVIOR

Journal acronym: BRAIN BEHAV

Volume number: 10

Issue number: 9

Number of pages: 6

ISSN: 2162-3279

DOI: http://dx.doi.org/10.1002/brb3.1772

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/48718771


Abstract
Objectives: Serum neurofilament light chain (sNfL) is a promising biomarker of MS activity, progression, and treatment response. The aim of the present study was to address whether sNfL concentrations are affected by supplementation of vitamin D and correlate with disease activity in interferon-beta-1b (IFNb-1b)-treated Finnish MS. Materials and

Methods: Serum samples were available of 32 participants of the Finnish vitamin D randomized controlled trial (17 vitamin D/15 placebo). Serum 25 hydroxyvitamin D was measured using radioimmunoassay and sNfL using single-molecule array (Simoa). Correlation of sNfL with brain magnetic resonance imaging (MRI) activity, burden of disease (BOD, mm(3)), and disability was assessed at the study baseline and at 52 weeks.

Results: Serum NfL concentrations were similar in the patients randomized to high-dose vitamin D and placebo at the study baseline and at month 12 follow-up (p-value). Concentrations of sNfL were higher in patients with Gadolinium-enhancing lesions in brain MRI: median (95% CI) sNfL was 14.84 (9.9-42.5) pg/ml and 11.39 (8.9-13.2) pg/ml in patients without Gd(+)lesions (p = .0144) and correlated with enhancing lesion volume (Pearsonr = .36,p = .037) at the study baseline but not at week 52. Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25-foot walk test.

Conclusion: In this small cohort of clinically stable IFN-treated Finnish MS patients, sNfL levels were similarly low in patients supplemented with high-dose vitamin D or placebo. Subclinical disease activity in MRI was associated with higher sNfL levels.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2022-07-04 at 17:56